WO2007029689A1 - 抗原提示細胞の活性化処理方法 - Google Patents
抗原提示細胞の活性化処理方法 Download PDFInfo
- Publication number
- WO2007029689A1 WO2007029689A1 PCT/JP2006/317535 JP2006317535W WO2007029689A1 WO 2007029689 A1 WO2007029689 A1 WO 2007029689A1 JP 2006317535 W JP2006317535 W JP 2006317535W WO 2007029689 A1 WO2007029689 A1 WO 2007029689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- cells
- group
- cell
- cancer
- Prior art date
Links
- 210000000612 antigen-presenting cell Anatomy 0.000 title claims abstract description 131
- 238000000034 method Methods 0.000 title claims abstract description 96
- 238000011282 treatment Methods 0.000 title claims description 26
- 230000004913 activation Effects 0.000 title claims description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 482
- 102000036639 antigens Human genes 0.000 claims abstract description 187
- 108091007433 antigens Proteins 0.000 claims abstract description 187
- 239000000427 antigen Substances 0.000 claims abstract description 174
- 201000010099 disease Diseases 0.000 claims abstract description 128
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 128
- 229940122361 Bisphosphonate Drugs 0.000 claims abstract description 54
- 150000004663 bisphosphonates Chemical class 0.000 claims abstract description 53
- 230000001939 inductive effect Effects 0.000 claims abstract description 30
- 206010070834 Sensitisation Diseases 0.000 claims abstract description 27
- 230000006698 induction Effects 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 114
- 201000011510 cancer Diseases 0.000 claims description 96
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 53
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 43
- 208000015181 infectious disease Diseases 0.000 claims description 35
- 210000004698 lymphocyte Anatomy 0.000 claims description 35
- 208000035473 Communicable disease Diseases 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 230000008313 sensitization Effects 0.000 claims description 25
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 21
- 150000004677 hydrates Chemical class 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 15
- 230000001235 sensitizing effect Effects 0.000 claims description 15
- 125000003277 amino group Chemical group 0.000 claims description 14
- 230000001640 apoptogenic effect Effects 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- 229960004276 zoledronic acid Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 230000003213 activating effect Effects 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims description 8
- 150000001875 compounds Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229960000759 risedronic acid Drugs 0.000 claims description 8
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 8
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 7
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 7
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 7
- 229960004343 alendronic acid Drugs 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000003282 alkyl amino group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 229960004585 etidronic acid Drugs 0.000 claims description 7
- 229960005236 ibandronic acid Drugs 0.000 claims description 7
- 229950006971 incadronic acid Drugs 0.000 claims description 7
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004104 aryloxy group Chemical group 0.000 claims description 6
- 230000001338 necrotic effect Effects 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000002458 infectious effect Effects 0.000 claims description 3
- 125000005110 aryl thio group Chemical group 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000003672 processing method Methods 0.000 claims 2
- 238000000338 in vitro Methods 0.000 abstract description 10
- 238000001727 in vivo Methods 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 229940002005 zometa Drugs 0.000 description 40
- 208000003174 Brain Neoplasms Diseases 0.000 description 39
- 101150080480 A27L gene Proteins 0.000 description 32
- 101100268532 Vaccinia virus (strain Western Reserve) VACWR150 gene Proteins 0.000 description 32
- 201000007270 liver cancer Diseases 0.000 description 26
- 208000014018 liver neoplasm Diseases 0.000 description 26
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 25
- 201000005202 lung cancer Diseases 0.000 description 25
- 208000020816 lung neoplasm Diseases 0.000 description 25
- 239000002609 medium Substances 0.000 description 23
- 239000002953 phosphate buffered saline Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 20
- 239000012091 fetal bovine serum Substances 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 18
- 238000012258 culturing Methods 0.000 description 17
- 206010006187 Breast cancer Diseases 0.000 description 14
- 208000026310 Breast neoplasm Diseases 0.000 description 14
- 206010009944 Colon cancer Diseases 0.000 description 13
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 13
- 230000004936 stimulating effect Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 12
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 11
- 206010035226 Plasma cell myeloma Diseases 0.000 description 11
- 208000002495 Uterine Neoplasms Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 201000001441 melanoma Diseases 0.000 description 11
- 201000000050 myeloid neoplasm Diseases 0.000 description 11
- 239000011886 peripheral blood Substances 0.000 description 11
- 210000005259 peripheral blood Anatomy 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 206010046766 uterine cancer Diseases 0.000 description 11
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 10
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 10
- 108010075704 HLA-A Antigens Proteins 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 208000008839 Kidney Neoplasms Diseases 0.000 description 9
- 206010038389 Renal cancer Diseases 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 201000010982 kidney cancer Diseases 0.000 description 9
- 210000005087 mononuclear cell Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000000453 Skin Neoplasms Diseases 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 210000001616 monocyte Anatomy 0.000 description 8
- 210000002826 placenta Anatomy 0.000 description 8
- 201000000849 skin cancer Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- -1 for example Chemical group 0.000 description 7
- 230000003449 preventive effect Effects 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 6
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 6
- 206010036790 Productive cough Diseases 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 6
- 230000000240 adjuvant effect Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 6
- 201000010881 cervical cancer Diseases 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- 210000000581 natural killer T-cell Anatomy 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000003802 sputum Anatomy 0.000 description 6
- 208000024794 sputum Diseases 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 206010017758 gastric cancer Diseases 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 210000003127 knee Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 102100020880 Kit ligand Human genes 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 3
- POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 3
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 3
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 101000891620 Homo sapiens TBC1 domain family member 1 Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 102000016200 MART-1 Antigen Human genes 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 102100040238 TBC1 domain family member 1 Human genes 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000000139 costimulatory effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- 206010046885 vaginal cancer Diseases 0.000 description 3
- 208000013139 vaginal neoplasm Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100022277 Fructose-bisphosphate aldolase A Human genes 0.000 description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 2
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 101000748141 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 32 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 102000003816 Interleukin-13 Human genes 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 2
- CZYWHNTUXNGDGR-UHFFFAOYSA-L Pamidronate disodium Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 102100023983 Sulfotransferase 1A3 Human genes 0.000 description 2
- 102100040050 Ubiquitin carboxyl-terminal hydrolase 32 Human genes 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 102000043557 human IFNG Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002642 osteogeneic effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 208000024361 placenta neoplasm Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- CAKRAHQRJGUPIG-UHFFFAOYSA-M sodium;[4-azaniumyl-1-hydroxy-1-[hydroxy(oxido)phosphoryl]butyl]-hydroxyphosphinate Chemical compound [Na+].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O CAKRAHQRJGUPIG-UHFFFAOYSA-M 0.000 description 2
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- 102100038369 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Human genes 0.000 description 1
- 102100025007 14-3-3 protein epsilon Human genes 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- LTPSRQRIPCVMKQ-UHFFFAOYSA-N 2-amino-5-methylbenzenesulfonic acid Chemical compound CC1=CC=C(N)C(S(O)(=O)=O)=C1 LTPSRQRIPCVMKQ-UHFFFAOYSA-N 0.000 description 1
- 102100036659 26S proteasome non-ATPase regulatory subunit 9 Human genes 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 102100024113 40S ribosomal protein S15a Human genes 0.000 description 1
- 102100039980 40S ribosomal protein S18 Human genes 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
- 102100021546 60S ribosomal protein L10 Human genes 0.000 description 1
- 102100022406 60S ribosomal protein L10a Human genes 0.000 description 1
- 102100037965 60S ribosomal protein L21 Human genes 0.000 description 1
- 102100021927 60S ribosomal protein L27a Human genes 0.000 description 1
- 102100038237 60S ribosomal protein L30 Human genes 0.000 description 1
- 102100040768 60S ribosomal protein L32 Human genes 0.000 description 1
- 102100036126 60S ribosomal protein L37a Human genes 0.000 description 1
- 102100040084 A-kinase anchor protein 9 Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 102100022908 ADP-ribosylation factor-like protein 1 Human genes 0.000 description 1
- 102100030674 ADP-ribosylation factor-like protein 6-interacting protein 1 Human genes 0.000 description 1
- 102100026397 ADP/ATP translocase 3 Human genes 0.000 description 1
- 101150012579 ADSL gene Proteins 0.000 description 1
- 102100031315 AP-2 complex subunit mu Human genes 0.000 description 1
- 102100033926 AP-3 complex subunit delta-1 Human genes 0.000 description 1
- 102100022890 ATP synthase subunit beta, mitochondrial Human genes 0.000 description 1
- 102100035972 ATPase GET3 Human genes 0.000 description 1
- 102100027647 Activin receptor type-2B Human genes 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 102100037399 Alanine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101100256840 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) sgpB gene Proteins 0.000 description 1
- 102100037242 Amiloride-sensitive sodium channel subunit alpha Human genes 0.000 description 1
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 description 1
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 description 1
- 102100028118 Annexin A11 Human genes 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 102100025511 Anti-Muellerian hormone type-2 receptor Human genes 0.000 description 1
- 102100021986 Apoptosis-stimulating of p53 protein 2 Human genes 0.000 description 1
- 102100027971 Arachidonate 12-lipoxygenase, 12R-type Human genes 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 102100028046 BAG family molecular chaperone regulator 5 Human genes 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021677 Baculoviral IAP repeat-containing protein 2 Human genes 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 101150104237 Birc3 gene Proteins 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100028252 Brain acid soluble protein 1 Human genes 0.000 description 1
- 102100027310 Bromodomain adjacent to zinc finger domain protein 1A Human genes 0.000 description 1
- 102100021576 Bromodomain adjacent to zinc finger domain protein 2A Human genes 0.000 description 1
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 101150108242 CDC27 gene Proteins 0.000 description 1
- 102100027194 CDP-diacylglycerol-inositol 3-phosphatidyltransferase Human genes 0.000 description 1
- 108010066050 CDP-diacylglycerol-inositol 3-phosphatidyltransferase Proteins 0.000 description 1
- 101100335058 Caenorhabditis elegans flp-9 gene Proteins 0.000 description 1
- 102100029303 Calcium-regulated heat-stable protein 1 Human genes 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 102100039510 Cancer/testis antigen 2 Human genes 0.000 description 1
- 102100027668 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Human genes 0.000 description 1
- 101710134395 Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100028003 Catenin alpha-1 Human genes 0.000 description 1
- 102100031266 Chromodomain-helicase-DNA-binding protein 3 Human genes 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100031552 Coactosin-like protein Human genes 0.000 description 1
- 102100022589 Coatomer subunit beta' Human genes 0.000 description 1
- 102100028250 Conserved oligomeric Golgi complex subunit 8 Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 102100034528 Core histone macro-H2A.1 Human genes 0.000 description 1
- 102100025525 Cullin-5 Human genes 0.000 description 1
- 102100025191 Cyclin-A2 Human genes 0.000 description 1
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 102100033589 DNA topoisomerase 2-beta Human genes 0.000 description 1
- 102100037377 DNA-(apurinic or apyrimidinic site) endonuclease 2 Human genes 0.000 description 1
- 102100032881 DNA-binding protein SATB1 Human genes 0.000 description 1
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 description 1
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 description 1
- 102100022258 Disks large homolog 5 Human genes 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102100020977 DnaJ homolog subfamily A member 1 Human genes 0.000 description 1
- 102100035966 DnaJ homolog subfamily A member 2 Human genes 0.000 description 1
- 102100029721 DnaJ homolog subfamily B member 1 Human genes 0.000 description 1
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 description 1
- 102100037573 Dual specificity protein phosphatase 12 Human genes 0.000 description 1
- 102100036654 Dynactin subunit 1 Human genes 0.000 description 1
- 102100034185 E3 ubiquitin-protein ligase RLIM Human genes 0.000 description 1
- 102100027416 E3 ubiquitin-protein ligase RNF103 Human genes 0.000 description 1
- 102100023431 E3 ubiquitin-protein ligase TRIM21 Human genes 0.000 description 1
- 101150115146 EEF2 gene Proteins 0.000 description 1
- 101150097734 EPHB2 gene Proteins 0.000 description 1
- 102100037249 Egl nine homolog 1 Human genes 0.000 description 1
- 102100023362 Elongation factor 1-gamma Human genes 0.000 description 1
- 102100031334 Elongation factor 2 Human genes 0.000 description 1
- 102100030208 Elongin-A Human genes 0.000 description 1
- 102100029988 Endoplasmic reticulum-Golgi intermediate compartment protein 3 Human genes 0.000 description 1
- 102100032450 Endothelial differentiation-related factor 1 Human genes 0.000 description 1
- 101710182961 Endothelial differentiation-related factor 1 Proteins 0.000 description 1
- 101710159618 Endothelial differentiation-related factor 1 homolog Proteins 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 102100038085 Eukaryotic translation initiation factor 3 subunit L Human genes 0.000 description 1
- 102100039737 Eukaryotic translation initiation factor 4 gamma 2 Human genes 0.000 description 1
- 102100022457 Eukaryotic translation initiation factor 4E-binding protein 3 Human genes 0.000 description 1
- 102100040834 FXYD domain-containing ion transport regulator 5 Human genes 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 102100021066 Fibroblast growth factor receptor substrate 2 Human genes 0.000 description 1
- 101710126950 Fibroblast growth factor receptor substrate 2 Proteins 0.000 description 1
- 102100031812 Fibulin-1 Human genes 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010038179 G-protein beta3 subunit Proteins 0.000 description 1
- 102100024515 GDP-L-fucose synthase Human genes 0.000 description 1
- 108700031843 GRB7 Adaptor Proteins 0.000 description 1
- 101150052409 GRB7 gene Proteins 0.000 description 1
- 102100028617 GRIP and coiled-coil domain-containing protein 2 Human genes 0.000 description 1
- 101710113436 GTPase KRas Proteins 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102100038073 General transcription factor II-I Human genes 0.000 description 1
- 102100032864 General transcription factor IIH subunit 2 Human genes 0.000 description 1
- 101100256841 Glossina morsitans morsitans sgp2 gene Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102100032563 Golgin subfamily A member 1 Human genes 0.000 description 1
- 102100033107 Growth factor receptor-bound protein 7 Human genes 0.000 description 1
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 description 1
- 102100035913 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-4 Human genes 0.000 description 1
- 102100039845 Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-8 Human genes 0.000 description 1
- 102100035346 Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 Human genes 0.000 description 1
- 102100024979 Guanine nucleotide-binding protein subunit beta-like protein 1 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 108700039143 HMGA2 Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102100028999 High mobility group protein HMGI-C Human genes 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102100021453 Histone deacetylase 5 Human genes 0.000 description 1
- 101150073387 Hmga2 gene Proteins 0.000 description 1
- 101000605571 Homo sapiens 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Proteins 0.000 description 1
- 101000760079 Homo sapiens 14-3-3 protein epsilon Proteins 0.000 description 1
- 101001136710 Homo sapiens 26S proteasome non-ATPase regulatory subunit 9 Proteins 0.000 description 1
- 101001118566 Homo sapiens 40S ribosomal protein S15a Proteins 0.000 description 1
- 101000811259 Homo sapiens 40S ribosomal protein S18 Proteins 0.000 description 1
- 101001108634 Homo sapiens 60S ribosomal protein L10 Proteins 0.000 description 1
- 101000755323 Homo sapiens 60S ribosomal protein L10a Proteins 0.000 description 1
- 101001117935 Homo sapiens 60S ribosomal protein L15 Proteins 0.000 description 1
- 101000661708 Homo sapiens 60S ribosomal protein L21 Proteins 0.000 description 1
- 101000753696 Homo sapiens 60S ribosomal protein L27a Proteins 0.000 description 1
- 101001101319 Homo sapiens 60S ribosomal protein L30 Proteins 0.000 description 1
- 101000672453 Homo sapiens 60S ribosomal protein L32 Proteins 0.000 description 1
- 101001092424 Homo sapiens 60S ribosomal protein L37a Proteins 0.000 description 1
- 101000890598 Homo sapiens A-kinase anchor protein 9 Proteins 0.000 description 1
- 101000974500 Homo sapiens ADP-ribosylation factor-like protein 1 Proteins 0.000 description 1
- 101000793552 Homo sapiens ADP-ribosylation factor-like protein 6-interacting protein 1 Proteins 0.000 description 1
- 101000718437 Homo sapiens ADP/ATP translocase 3 Proteins 0.000 description 1
- 101000796047 Homo sapiens AP-2 complex subunit mu Proteins 0.000 description 1
- 101000779252 Homo sapiens AP-3 complex subunit delta-1 Proteins 0.000 description 1
- 101000903027 Homo sapiens ATP synthase subunit beta, mitochondrial Proteins 0.000 description 1
- 101001074983 Homo sapiens ATPase GET3 Proteins 0.000 description 1
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 description 1
- 101000879354 Homo sapiens Alanine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000718041 Homo sapiens Aldo-keto reductase family 1 member B10 Proteins 0.000 description 1
- 101000740448 Homo sapiens Amiloride-sensitive sodium channel subunit alpha Proteins 0.000 description 1
- 101000768066 Homo sapiens Annexin A11 Proteins 0.000 description 1
- 101000924474 Homo sapiens Annexin A2 Proteins 0.000 description 1
- 101000693801 Homo sapiens Anti-Muellerian hormone type-2 receptor Proteins 0.000 description 1
- 101000752711 Homo sapiens Apoptosis-stimulating of p53 protein 2 Proteins 0.000 description 1
- 101000578469 Homo sapiens Arachidonate 12-lipoxygenase, 12R-type Proteins 0.000 description 1
- 101000929698 Homo sapiens Aspartate aminotransferase, cytoplasmic Proteins 0.000 description 1
- 101000697498 Homo sapiens BAG family molecular chaperone regulator 5 Proteins 0.000 description 1
- 101000935689 Homo sapiens Brain acid soluble protein 1 Proteins 0.000 description 1
- 101000937778 Homo sapiens Bromodomain adjacent to zinc finger domain protein 1A Proteins 0.000 description 1
- 101000971147 Homo sapiens Bromodomain adjacent to zinc finger domain protein 2A Proteins 0.000 description 1
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 description 1
- 101100166621 Homo sapiens CD80 gene Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101000989513 Homo sapiens Calcium-regulated heat-stable protein 1 Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000889345 Homo sapiens Cancer/testis antigen 2 Proteins 0.000 description 1
- 101000859063 Homo sapiens Catenin alpha-1 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000777071 Homo sapiens Chromodomain-helicase-DNA-binding protein 3 Proteins 0.000 description 1
- 101000940352 Homo sapiens Coactosin-like protein Proteins 0.000 description 1
- 101000899916 Homo sapiens Coatomer subunit beta' Proteins 0.000 description 1
- 101000860644 Homo sapiens Conserved oligomeric Golgi complex subunit 8 Proteins 0.000 description 1
- 101001067929 Homo sapiens Core histone macro-H2A.1 Proteins 0.000 description 1
- 101000856414 Homo sapiens Cullin-5 Proteins 0.000 description 1
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 description 1
- 101000806823 Homo sapiens DNA-(apurinic or apyrimidinic site) endonuclease 2 Proteins 0.000 description 1
- 101000655234 Homo sapiens DNA-binding protein SATB1 Proteins 0.000 description 1
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 description 1
- 101000902114 Homo sapiens Disks large homolog 5 Proteins 0.000 description 1
- 101000931227 Homo sapiens DnaJ homolog subfamily A member 1 Proteins 0.000 description 1
- 101000931210 Homo sapiens DnaJ homolog subfamily A member 2 Proteins 0.000 description 1
- 101000866018 Homo sapiens DnaJ homolog subfamily B member 1 Proteins 0.000 description 1
- 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 description 1
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 101000929626 Homo sapiens Dynactin subunit 1 Proteins 0.000 description 1
- 101000711924 Homo sapiens E3 ubiquitin-protein ligase RLIM Proteins 0.000 description 1
- 101000650319 Homo sapiens E3 ubiquitin-protein ligase RNF103 Proteins 0.000 description 1
- 101000685877 Homo sapiens E3 ubiquitin-protein ligase TRIM21 Proteins 0.000 description 1
- 101000881648 Homo sapiens Egl nine homolog 1 Proteins 0.000 description 1
- 101001050451 Homo sapiens Elongation factor 1-gamma Proteins 0.000 description 1
- 101001011859 Homo sapiens Elongin-A Proteins 0.000 description 1
- 101001010804 Homo sapiens Endoplasmic reticulum-Golgi intermediate compartment protein 3 Proteins 0.000 description 1
- 101000810389 Homo sapiens Eukaryotic translation initiation factor 3 subunit L Proteins 0.000 description 1
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 1
- 101000678288 Homo sapiens Eukaryotic translation initiation factor 4E-binding protein 3 Proteins 0.000 description 1
- 101000893718 Homo sapiens FXYD domain-containing ion transport regulator 5 Proteins 0.000 description 1
- 101001065276 Homo sapiens Fibulin-1 Proteins 0.000 description 1
- 101000755879 Homo sapiens Fructose-bisphosphate aldolase A Proteins 0.000 description 1
- 101001052793 Homo sapiens GDP-L-fucose synthase Proteins 0.000 description 1
- 101100015378 Homo sapiens GNB1L gene Proteins 0.000 description 1
- 101001058870 Homo sapiens GRIP and coiled-coil domain-containing protein 2 Proteins 0.000 description 1
- 101001032427 Homo sapiens General transcription factor II-I Proteins 0.000 description 1
- 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 1
- 101001014628 Homo sapiens Golgin subfamily A member 1 Proteins 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101001073261 Homo sapiens Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 description 1
- 101000911772 Homo sapiens Hsc70-interacting protein Proteins 0.000 description 1
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 1
- 101000942967 Homo sapiens Leukemia inhibitory factor Proteins 0.000 description 1
- 101001001294 Homo sapiens Lysosomal acid phosphatase Proteins 0.000 description 1
- 101000914251 Homo sapiens Major centromere autoantigen B Proteins 0.000 description 1
- 101000582846 Homo sapiens Mediator of RNA polymerase II transcription subunit 22 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 101001057131 Homo sapiens Melanoma-associated antigen D4 Proteins 0.000 description 1
- 101000632037 Homo sapiens NAD(P)H-hydrate epimerase Proteins 0.000 description 1
- 101000583239 Homo sapiens Nicotinate-nucleotide pyrophosphorylase [carboxylating] Proteins 0.000 description 1
- 101000866795 Homo sapiens Non-histone chromosomal protein HMG-14 Proteins 0.000 description 1
- 101000886818 Homo sapiens PDZ domain-containing protein GIPC1 Proteins 0.000 description 1
- 101000651906 Homo sapiens Paired amphipathic helix protein Sin3a Proteins 0.000 description 1
- 101001094872 Homo sapiens Plexin-C1 Proteins 0.000 description 1
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 description 1
- 101000574013 Homo sapiens Pre-mRNA-processing factor 40 homolog A Proteins 0.000 description 1
- 101000952113 Homo sapiens Probable ATP-dependent RNA helicase DDX5 Proteins 0.000 description 1
- 101000705766 Homo sapiens Proteasome activator complex subunit 3 Proteins 0.000 description 1
- 101000933607 Homo sapiens Protein BTG3 Proteins 0.000 description 1
- 101000880769 Homo sapiens Protein SSX1 Proteins 0.000 description 1
- 101000880774 Homo sapiens Protein SSX4 Proteins 0.000 description 1
- 101000915575 Homo sapiens Protein ZNRD2 Proteins 0.000 description 1
- 101000658082 Homo sapiens Putative U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 1 Proteins 0.000 description 1
- 101000668170 Homo sapiens RNA-binding motif, single-stranded-interacting protein 2 Proteins 0.000 description 1
- 101001076715 Homo sapiens RNA-binding protein 39 Proteins 0.000 description 1
- 101000685886 Homo sapiens RNA-binding protein RO60 Proteins 0.000 description 1
- 101000712958 Homo sapiens Ras association domain-containing protein 1 Proteins 0.000 description 1
- 101001077405 Homo sapiens Ras-related protein Rab-5C Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 description 1
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 description 1
- 101000984533 Homo sapiens Ribosome biogenesis protein BMS1 homolog Proteins 0.000 description 1
- 101000631899 Homo sapiens Ribosome maturation protein SBDS Proteins 0.000 description 1
- 101001093937 Homo sapiens SEC14-like protein 1 Proteins 0.000 description 1
- 101100256651 Homo sapiens SENP6 gene Proteins 0.000 description 1
- 101100311209 Homo sapiens STARD10 gene Proteins 0.000 description 1
- 101000587438 Homo sapiens Serine/arginine-rich splicing factor 5 Proteins 0.000 description 1
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 101000864070 Homo sapiens Smoothelin Proteins 0.000 description 1
- 101000665025 Homo sapiens Sorting nexin-6 Proteins 0.000 description 1
- 101000688561 Homo sapiens Sphingosine-1-phosphate lyase 1 Proteins 0.000 description 1
- 101000878981 Homo sapiens Squalene synthase Proteins 0.000 description 1
- 101000648153 Homo sapiens Stress-induced-phosphoprotein 1 Proteins 0.000 description 1
- 101000661446 Homo sapiens Succinate-CoA ligase [ADP-forming] subunit beta, mitochondrial Proteins 0.000 description 1
- 101000643620 Homo sapiens Synaptonemal complex protein 1 Proteins 0.000 description 1
- 101000697800 Homo sapiens Syntaxin-4 Proteins 0.000 description 1
- 101000835696 Homo sapiens T-complex protein 1 subunit theta Proteins 0.000 description 1
- 101000759312 Homo sapiens Tetratricopeptide repeat protein 12 Proteins 0.000 description 1
- 101000844686 Homo sapiens Thioredoxin reductase 1, cytoplasmic Proteins 0.000 description 1
- 101000648075 Homo sapiens Trafficking protein particle complex subunit 1 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 101000652332 Homo sapiens Transcription factor SOX-1 Proteins 0.000 description 1
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 1
- 101000715069 Homo sapiens Transcription initiation factor TFIID subunit 10 Proteins 0.000 description 1
- 101000657366 Homo sapiens Transcription initiation factor TFIID subunit 7 Proteins 0.000 description 1
- 101000652684 Homo sapiens Transcriptional adapter 3 Proteins 0.000 description 1
- 101000894525 Homo sapiens Transforming growth factor-beta-induced protein ig-h3 Proteins 0.000 description 1
- 101000801742 Homo sapiens Triosephosphate isomerase Proteins 0.000 description 1
- 101000801701 Homo sapiens Tropomyosin alpha-1 chain Proteins 0.000 description 1
- 101000851357 Homo sapiens Troponin T, slow skeletal muscle Proteins 0.000 description 1
- 101000835634 Homo sapiens Tubulin-folding cofactor B Proteins 0.000 description 1
- 101000835787 Homo sapiens Tudor domain-containing protein 3 Proteins 0.000 description 1
- 101000610980 Homo sapiens Tumor protein D52 Proteins 0.000 description 1
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 1
- 101000641003 Homo sapiens Tyrosine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000658084 Homo sapiens U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Proteins 0.000 description 1
- 101000607639 Homo sapiens Ubiquilin-2 Proteins 0.000 description 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 1
- 101000809243 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 10 Proteins 0.000 description 1
- 101000644815 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 16 Proteins 0.000 description 1
- 101000644843 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 19 Proteins 0.000 description 1
- 101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 1
- 101000809257 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 4 Proteins 0.000 description 1
- 101000772901 Homo sapiens Ubiquitin-conjugating enzyme E2 D2 Proteins 0.000 description 1
- 101000807306 Homo sapiens Ubiquitin-like modifier-activating enzyme 1 Proteins 0.000 description 1
- 101000975067 Homo sapiens Ubiquitin-like modifier-activating enzyme ATG7 Proteins 0.000 description 1
- 101001030255 Homo sapiens Unconventional myosin-XVIIIa Proteins 0.000 description 1
- 101000771982 Homo sapiens Vacuolar protein sorting-associated protein 45 Proteins 0.000 description 1
- 101000742579 Homo sapiens Vascular endothelial growth factor B Proteins 0.000 description 1
- 101000904228 Homo sapiens Vesicle transport protein GOT1A Proteins 0.000 description 1
- 101000904204 Homo sapiens Vesicle transport protein GOT1B Proteins 0.000 description 1
- 101000823782 Homo sapiens Y-box-binding protein 3 Proteins 0.000 description 1
- 101000744935 Homo sapiens Zinc finger protein 202 Proteins 0.000 description 1
- 101000782169 Homo sapiens Zinc finger protein 232 Proteins 0.000 description 1
- 101000785712 Homo sapiens Zinc finger protein 282 Proteins 0.000 description 1
- 101000723902 Homo sapiens Zinc finger protein 292 Proteins 0.000 description 1
- 101000976643 Homo sapiens Zinc finger protein ZIC 2 Proteins 0.000 description 1
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- 108010007666 IMP cyclohydrolase Proteins 0.000 description 1
- 102100020796 Inosine 5'-monophosphate cyclohydrolase Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 102100035699 Lysosomal acid phosphatase Human genes 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100025833 Major centromere autoantigen B Human genes 0.000 description 1
- 102100030223 Mediator of RNA polymerase II transcription subunit 22 Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 102100021769 Mitochondrial 2-oxoglutarate/malate carrier protein Human genes 0.000 description 1
- 102100030105 Mitochondrial ornithine transporter 2 Human genes 0.000 description 1
- 102100031307 Mitochondrial uncoupling protein 4 Human genes 0.000 description 1
- 101100166793 Mus musculus Cela2a gene Proteins 0.000 description 1
- 101100366528 Mus musculus Spsb3 gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102100028167 NAD(P)H-hydrate epimerase Human genes 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102100030830 Nicotinate-nucleotide pyrophosphorylase [carboxylating] Human genes 0.000 description 1
- 102100031353 Non-histone chromosomal protein HMG-14 Human genes 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102100039983 PDZ domain-containing protein GIPC1 Human genes 0.000 description 1
- 102100027334 Paired amphipathic helix protein Sin3a Human genes 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 102100027370 Parathymosin Human genes 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 102100035381 Plexin-C1 Human genes 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 description 1
- 102100025822 Pre-mRNA-processing factor 40 homolog A Human genes 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 102100037434 Probable ATP-dependent RNA helicase DDX5 Human genes 0.000 description 1
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100031298 Proteasome activator complex subunit 3 Human genes 0.000 description 1
- 102100026035 Protein BTG3 Human genes 0.000 description 1
- 102100037687 Protein SSX1 Human genes 0.000 description 1
- 102100037727 Protein SSX4 Human genes 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 102100035035 Putative U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 1 Human genes 0.000 description 1
- 102100039690 RNA-binding motif, single-stranded-interacting protein 2 Human genes 0.000 description 1
- 102100025858 RNA-binding protein 39 Human genes 0.000 description 1
- 102100023433 RNA-binding protein RO60 Human genes 0.000 description 1
- 102100033243 Ras association domain-containing protein 1 Human genes 0.000 description 1
- 102100025138 Ras-related protein Rab-5C Human genes 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 description 1
- 102100027057 Ribosome biogenesis protein BMS1 homolog Human genes 0.000 description 1
- 102100028750 Ribosome maturation protein SBDS Human genes 0.000 description 1
- 102100027160 RuvB-like 1 Human genes 0.000 description 1
- 101710169742 RuvB-like protein 1 Proteins 0.000 description 1
- 102100035214 SEC14-like protein 1 Human genes 0.000 description 1
- 108091006751 SLC22A17 Proteins 0.000 description 1
- 108091006417 SLC25A11 Proteins 0.000 description 1
- 108091006711 SLC25A2 Proteins 0.000 description 1
- 108091006457 SLC25A27 Proteins 0.000 description 1
- 101150038317 SSP1 gene Proteins 0.000 description 1
- 102100025253 START domain-containing protein 10 Human genes 0.000 description 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 1
- 101100125020 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pss1 gene Proteins 0.000 description 1
- 101100018019 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ssc1 gene Proteins 0.000 description 1
- 108010061477 Securin Proteins 0.000 description 1
- 102000012152 Securin Human genes 0.000 description 1
- 102100023713 Sentrin-specific protease 6 Human genes 0.000 description 1
- 102100029703 Serine/arginine-rich splicing factor 5 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 102100027388 Signal recognition particle 19 kDa protein Human genes 0.000 description 1
- 101710122555 Signal recognition particle 19 kDa protein Proteins 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 102100029937 Smoothelin Human genes 0.000 description 1
- 102100021542 Solute carrier family 22 member 17 Human genes 0.000 description 1
- 102100038626 Sorting nexin-6 Human genes 0.000 description 1
- 102100024239 Sphingosine-1-phosphate lyase 1 Human genes 0.000 description 1
- 102100037997 Squalene synthase Human genes 0.000 description 1
- 102100026760 StAR-related lipid transfer protein 7, mitochondrial Human genes 0.000 description 1
- 101150000240 Stard7 gene Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100025292 Stress-induced-phosphoprotein 1 Human genes 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100037811 Succinate-CoA ligase [ADP-forming] subunit beta, mitochondrial Human genes 0.000 description 1
- 102100036234 Synaptonemal complex protein 1 Human genes 0.000 description 1
- 102100027975 Syntaxin-4 Human genes 0.000 description 1
- 102100026311 T-complex protein 1 subunit theta Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- 102100023284 Tetratricopeptide repeat protein 12 Human genes 0.000 description 1
- 102100031208 Thioredoxin reductase 1, cytoplasmic Human genes 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 102100034195 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 208000006842 Tonsillar Neoplasms Diseases 0.000 description 1
- 102100025256 Trafficking protein particle complex subunit 1 Human genes 0.000 description 1
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 description 1
- 102100030248 Transcription factor SOX-1 Human genes 0.000 description 1
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 1
- 102100036677 Transcription initiation factor TFIID subunit 10 Human genes 0.000 description 1
- 102100034748 Transcription initiation factor TFIID subunit 7 Human genes 0.000 description 1
- 102100030836 Transcriptional adapter 3 Human genes 0.000 description 1
- 102100021398 Transforming growth factor-beta-induced protein ig-h3 Human genes 0.000 description 1
- 102100033598 Triosephosphate isomerase Human genes 0.000 description 1
- 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 1
- 102100036860 Troponin T, slow skeletal muscle Human genes 0.000 description 1
- 102100026482 Tubulin-folding cofactor B Human genes 0.000 description 1
- 102100026362 Tudor domain-containing protein 3 Human genes 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040418 Tumor protein D52 Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 1
- 102100034298 Tyrosine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102100035036 U2 small nuclear ribonucleoprotein auxiliary factor 35 kDa subunit-related protein 2 Human genes 0.000 description 1
- 102100027244 U4/U6.U5 tri-snRNP-associated protein 1 Human genes 0.000 description 1
- 101710155955 U4/U6.U5 tri-snRNP-associated protein 1 Proteins 0.000 description 1
- 102100039933 Ubiquilin-2 Human genes 0.000 description 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 1
- 102100020730 Ubiquitin carboxyl-terminal hydrolase 16 Human genes 0.000 description 1
- 102100020728 Ubiquitin carboxyl-terminal hydrolase 19 Human genes 0.000 description 1
- 102100038463 Ubiquitin carboxyl-terminal hydrolase 4 Human genes 0.000 description 1
- 102100030439 Ubiquitin-conjugating enzyme E2 D2 Human genes 0.000 description 1
- 102100037160 Ubiquitin-like modifier-activating enzyme 1 Human genes 0.000 description 1
- 102100022979 Ubiquitin-like modifier-activating enzyme ATG7 Human genes 0.000 description 1
- 102100038932 Unconventional myosin-XVIIIa Human genes 0.000 description 1
- 201000008616 Usher syndrome type 1 Diseases 0.000 description 1
- 102100029495 Vacuolar protein sorting-associated protein 45 Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100024010 Vesicle transport protein GOT1A Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102100022221 Y-box-binding protein 3 Human genes 0.000 description 1
- 102100039976 Zinc finger protein 202 Human genes 0.000 description 1
- 102100036549 Zinc finger protein 232 Human genes 0.000 description 1
- 102100026417 Zinc finger protein 282 Human genes 0.000 description 1
- 102100028431 Zinc finger protein 292 Human genes 0.000 description 1
- 102100035804 Zinc finger protein 823 Human genes 0.000 description 1
- 102100023492 Zinc finger protein ZIC 2 Human genes 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- RLIRIVMEKVNVQX-UHFFFAOYSA-L disodium;(2-cycloheptyl-1-phosphonatoethyl)-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound [Na+].[Na+].OP([O-])(=O)C(P(O)([O-])=O)CC1CCCCCC1 RLIRIVMEKVNVQX-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010065889 glycyl-leucyl-cysteinyl-threonyl-leucyl-valyl-alanyl-methionyl-leucine Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000054189 human CD80 Human genes 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 108010083982 monoamine-sulfating phenol sulfotransferase Proteins 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- PUPNJSIFIXXJCH-UHFFFAOYSA-N n-(4-hydroxyphenyl)-2-(1,1,3-trioxo-1,2-benzothiazol-2-yl)acetamide Chemical compound C1=CC(O)=CC=C1NC(=O)CN1S(=O)(=O)C2=CC=CC=C2C1=O PUPNJSIFIXXJCH-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464491—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to an antigen-presenting cell co-sensitized with a bisphosphonate and a disease antigen.
- the present invention also relates to a medicament containing the antigen-presenting cell, a therapeutic / preventive method using the rod-shaped cell, and a method for inducing immunocompetent cells using the antigen-presenting cell.
- the present invention relates to an immunocompetent cell induced by the induction method, a medicament containing the immunocompetent cell, and a therapeutic / preventive method using the immunocompetent cell.
- LAK Lymphokine Activated Killer
- lymphocytes are activated by lymphokines outside the body and returned to the body
- cytotoxic T cells that specifically recognize and damage lesions (Cytotoxic T cells) CTL therapy using Lymphocyte (hereinafter referred to as CTL) and rod cell therapy.
- the aforementioned rod-shaped cell therapy uses a rod-shaped cell that is presented to MH C (Major Histocompatibility antigen Complex) after processing a disease antigen directly or in a cell.
- the disease antigen to be presented include cancer antigen protein or peptide, infectious disease antigen protein or peptide, or a part thereof (see, for example, Non-Patent Document 1 and Non-Patent Document 2).
- Disease antigen-specific CTL can be induced in vitro (in vitro) by incubating rod cells and lymphocytes sensitized with a disease antigen and stimulating the lymphocytes with the rod cells.
- a disease antigen for example, when a rod-like cell sensitized with a cancer antigen protein or peptide or an infectious disease antigen protein or peptide is used, the increase in the disease antigen CTL induced by a single mixed culture does not use the aforementioned rod-shaped cell. It is 5 to 20 times the case.
- the induction efficiency of the disease antigen-specific CTL in vivo that is, It is known that the ratio of CTL to total lymphocytes increases to 2 to 14 times.
- the rods in addition to sensitizing rod cells with disease antigens, the rods also contain drugs that react with Toll-like receptors (hereinafter referred to as TLR) on rod cells.
- TLR Toll-like receptors
- antigen presenting molecules other than MHC molecules on rod cells such as glycolipids on CD Id (Cluster Differ entiation Id) molecules
- iNKT invariant Natural Killer T cells
- This is a method for increasing the induction efficiency (adjuvant effect through immunocompetent cells other than disease antigen-specific CTLs, for example, see Non-Patent Document 5 and Non-Patent Document 6).
- the disease antigen-specific CTL by the direct adjuvant effect through the TLR or the indirect adjuvant effect through the immunocompetent cells other than the disease antigen-specific CTL.
- the increase in induction is about 4 times 6 times that in the case where these adjuvants are not used (in vitro). Therefore, development of a technique that can induce disease antigen-specific CTL more efficiently is desired.
- Non-Patent Document 1 Blood 2004, 103,383-389
- Non-Patent Document 2 Proc Natl Acad Sci U S A. 2001, 98, 8809-8814
- Non-Patent Document 3 Nat Rev Immunol. 2004, 4, 449-511
- Non Patent Literature 4 Cancer Res. 2004, 64, 5461-5470
- Non-Patent Document 5 J Clin Invest. 2004, 114, 1800-1811
- Non-Patent Document 6 J Exp Med. 2002, 195, 617-624 Disclosure of the invention
- the present invention has been made in view of the above circumstances, and immunocompetent cells containing predominantly disease antigen-specific CD8 + CTL and / or 0 ⁇ ⁇ cells are selected in vivo and / or in vitro.
- a method for activating antigen-presenting cells eg, rod-like cells
- a medicament containing the activated antigen-presenting cells e.g, a treatment / prevention method using the activated antigen-presenting cells
- Method for inducing immunocompetent cells including disease antigen-specific CD8 + CTL and Z or ⁇ sputum cells using the activated antigen-presenting cells, immunocompetent cells induced by the method, including the immunocompetent cells Provided are a medicine and a method for treatment and prevention using the immunocompetent cell.
- the present inventors have studied to solve the above problems.
- the proportion of disease antigen-specific CTL and ⁇ ⁇ ⁇ cells in total lymphocytes when sensitized with bisphosphonate in addition to sensitizing rod cells with disease antigen compared to when bisphosphonate was not added
- the proportion of disease antigen-specific CTL in all lymphocytes is about 100 times higher and the proportion of ⁇ ⁇ ⁇ cells is about three times higher than without bisphosphonate.
- Antigen-specific CTL can be about 90 times and ⁇ ⁇ cells can be about 6 times.
- the present invention is not limited to these values. According to the present invention, further development of immune cell therapy that induces disease antigen-specific CD8 + CTL and ⁇ or ⁇ ⁇ cells to treat / prevent cancer and ⁇ or infection is promoted.
- the present invention is as follows.
- An antigen-presenting cell activation treatment method comprising the step of co-sensitizing the antigen-presenting cell with a bisphosphonate and a disease antigen
- antigen-presenting cell activation treatment method wherein the antigen-presenting cell is selected from the group consisting of rod-shaped cells, immature rod-shaped cells, and artificial antigen-presenting cells,
- the bisphosphonate is a compound represented by the following general formula (I), a salt thereof, and These hydrates,
- R is a hydrogen atom or a lower alkyl group, and R and R are each
- R and R examples include a halogen atom, a lower alkyl group, and a hydroxyl group.
- a thiol group, an amino group, an alkoxy group, an aryl group, an aryl group, an aryloxy group, an alkylthio group, a cycloalkyl group, a heterocyclic group, and the like group force selected The antigen-presenting cell according to (1) or (2) Activation treatment method.
- the bisphosphonate is selected from the group consisting of zoledronic acid, nomidronic acid, alendronic acid, risedronic acid, ibandronic acid, incadronic acid, etidronic acid, their salts, and their hydrates.
- Kashi et al. (3) The activity of the antigen-presenting cell according to any one of V.
- the concentration of the bisphosphonate in the sensitization is 0.001 to 20 i u M (1) to (4) The antigen-presenting cell activation treatment method according to any one of V,
- the disease antigen is selected from the group consisting of cancer antigen or infectious disease antigen protein, peptide thereof, cell lysate of cancer cell or infectious disease cell, apoptotic cell, necrotic cell, and heat-treated product thereof.
- the concentration of the disease antigen in the sensitization is 0.01 to 20
- a method for producing an active antigen-presenting cell which comprises treating an antigen-presenting cell with the activation method described in any one of (1) to (9) V, Production method,
- a pharmaceutical composition for cancer and Z or infection comprising the activated antigen-presenting cell according to (11),
- An immunocompetent cell induction method comprising the following steps (i) and (ii):
- the immunocompetent cell force to be induced The method for inducing an immunocompetent cell according to (16), comprising at least one of disease antigen-specific CD8 + CTL and ⁇ ⁇ cells,
- the bisphosphonate is a compound represented by the following general formula (I), a salt thereof, and a hydrate thereof: Conversion:
- R is a hydrogen atom or a lower alkyl group, and R and R are each
- R and R examples include a halogen atom, a lower alkyl group, and a hydroxyl group.
- the group force is selected from: a thiol group, an amino group, an alkoxy group, an aryl group, an aryl group, an aryloxy group, an alkylthio group, a cycloalkyl group, and a heterocyclic group Induction method of responsible cells.
- the bisphosphonate is selected from the group power consisting of zoledronic acid, nomidronic acid, alendronic acid, risedronic acid, ibandronic acid, incadronic acid, etidronic acid, salts thereof, and hydrates thereof ( 16) to (19), the method for inducing immunocompetent cells described in any one of
- the disease antigen is selected from the group consisting of cancer antigen or infectious disease antigen protein, peptide thereof, cell lysate of cancer cell or infectious disease cell, apoptotic cell, necrotic cell, and heat-treated product thereof.
- (16) to (22) V the method for inducing an immunocompetent cell according to any one of the above
- (24) The method for inducing immunocompetent cells according to any one of (16) to (23) V, wherein the concentration of the disease antigen in the sensitization is 0.01-20 8 ! 11,
- a method for producing an immunocompetent cell comprising producing an immunocompetent cell comprising inducing the immunocompetent cell by the induction method according to any one of (16) to (25),
- a pharmaceutical composition for cancer and epilepsy or infection comprising the immunocompetent cell according to (27),
- (31) The method for preventing and treating cancer and epilepsy or infectious disease according to (30), wherein the antigen-presenting cell is autologous or derived from another family having the same HLA.
- the bisphosphonate is a compound represented by the following general formula (I), a salt thereof, and a hydrate thereof,
- R is a hydrogen atom or a lower alkyl group, and R and R are each
- R and R examples include a halogen atom, a lower alkyl group, and a hydroxyl group.
- An activation promoter for the antigen-presenting cells produced
- the bisphosphonate is selected from the group consisting of zoledronic acid, nomidronic acid, alendronic acid, risedronic acid, ibandronic acid, incadronic acid, etidronic acid, their salts, and their hydrates (32) (34) V, an activation promoter for antigen-presenting cells when sensitized with the disease antigen described in any one of the above.
- FIG. 1 is a graph showing an example of the results of measuring the ratio of A27L-specific CD8 + CTL.
- the first 3 ⁇ 4-shaped cocoon production of the activated Kumahara presentation
- the activated antigen-presenting cell of the present invention is an antigen-presenting cell co-sensitized with bisphosphonate and a disease antigen.
- the antigen-presenting cells used in the present invention are not particularly limited.
- immature rod cells In addition, mature rod cells, other antigen-presenting cells, artificial antigen-presenting cells, and mixtures thereof may be used. Among these, immature rod cells and mature rod cells are more preferable, and immature rod cells are more preferable. This is because immature rod cells can induce disease antigen-specific CTL and Z or ⁇ ⁇ cells more suitably when sensitized with bisphosphonate and disease antigen.
- the artificial antigen-presenting cell is an artificially presented antigen-presenting cell that expresses, for example, at least major histocompatibility antigen ( ⁇ C) class I and costimulatory molecules (for example, CD80, CD86, etc.).
- the artificial antigen-presenting cells may be those obtained by modifying a tumor-derived cell line to express MHC class I and costimulatory molecules as described above.
- the cell lines include breast cancer-derived MDA-MB-231 (class I antigen HLA-A * 0201), renal cancer-derived TUHR10TKB (class I antigen HLA-A * 020lZA * 2402), gastric cancer-derived JR-st strain (class I antigen HLA-A * 2402) and the like. These cell lines can be obtained from, for example, ATCC and RIKEN BioResource Center.
- the production of the artificial antigen-presenting cells is disclosed in US Publication No. US-2005-0048 646-A1, the entire contents of which are incorporated herein by reference.
- the bisphosphonate is not particularly limited and is an analog of pyrophosphate, in which P (O—P) of the pyrophosphate skeleton is substituted with C (carbon atom).
- a compound examples of the bisphosphonate used in the present invention include a compound represented by the following general formula (I), a salt thereof, and a hydrate thereof.
- R is a hydrogen atom or a lower alkyl group, and R and R are each
- R and R may form part of the same cyclic structure.
- R and R examples include a halogen atom, a lower alkyl group, and a hydride.
- It is selected from the group consisting of oral xyl groups, thiol groups, amino groups, alkoxy groups, aryl groups, arylthio groups, aryloxy groups, alkylthio groups, cycloalkyl groups, heterocyclic groups and the like.
- examples of the halogen atom include, for example, a fluoro atom, a black-atom atom, and an aromatic atom;
- examples of the alkyl group include, for example, methyl, ethyl, propyl, isopropyl, butyl, pentyl, heptyl, octyl. , Straight chain or branched chain such as pentade group
- aryl group for example, a phenyl, naphthyl group, etc .
- aralkyl group for example, an aryl lower alkyl group, etc .
- a cycloalkyl group for example, cyclooctyl, adamantyl, etc. C—C cycloalkyl group, etc .
- bisphosphonates are preferred.
- examples include bisphosphonates that have a bone resorption inhibitory action and are generally used as therapeutic agents for osteoporosis.
- Examples include zoledronic acid, its salts and Z or their hydrates (eg sodium zoledronic acid hydrate (Zometa (trade name), Novartis Pharma)), pamidronic acid, its salts and Z or their hydrates.
- the “disease” is not particularly limited, and examples thereof include cancer and infectious diseases.
- the cancer is not particularly limited and includes any cancer, such as cancer that is difficult to treat (including precancerous conditions).
- the infectious disease is not particularly limited, and examples thereof include viral infections such as AIDS and hepatitis B and C, cell infections, bacterial infections, fungal infections, and protozoal infections.
- the form of the disease antigen used in the present invention is not particularly limited, and examples thereof include cancer antigens or infectious disease antigen proteins and peptides thereof. Examples of the disease antigen include cancer cell or infectious disease cell lysates, apoptotic cells, necrotic cells, and heat-treated products thereof.
- any antigen can be used regardless of the type of cancer of the cancer antigen.
- any cancer antigen such as prostate cancer, liver cancer or pancreatic cancer can be used.
- the cancer antigen include those encoded by the MAGE gene family such as MAGE1, MAGE3, GAGE, BAGE and RAGE.
- Other cancer antigens include, for example, cancer antigens caused by mutations in p53, K-ras, CDK4, and bcl-cabl gene products, and overexpression in cancer cells such as c-erb2 (neu) protein
- cancer antigens and carcinogenic virus antigens such as HPV-16 E7 protein.
- tumor fetal antigens such as carcinoembryonic antigen (CEA) and human fetoprotein (AFP), prostate specific antigen, and CD-10 (CALLA antigen) expressed on leukemia and lymphoma B cells. Minute antigens can also be used.
- CEA carcinoembryonic antigen
- AFP human fetoprotein
- CALLA antigen CD-10 expressed on leukemia and lymphoma B cells. Minute antigens can also be used.
- infectious disease of the infectious disease antigen is not particularly limited, and among viral infectious diseases such as AIDS, hepatitis B, Epstein Barr virus (EBV) infection, HPV infection, etc. Intractable diseases are also included. Parasite antigens such as the malaria parasite sporozoide protein can also be used.
- a synthetic peptide can be used as the disease antigen peptide.
- cancer antigen protein or peptide for example, those listed in Tables 1 to 3 below can be used, and these can be easily used by those skilled in the art. Can be obtained or synthesized.
- AIBP renal cancer CDC27 Melano EIF4EBP3 Linha'oma
- CENF Breast cancer ETV6-AML1 Acute monocytic leukemia
- APC Colorectal cancer etc. COR01A Brain tumor etc. GDF11 Brain tumor
- BAZ2A Carcinoma DLG5 Brain tumor HDAC5 Large intestine, rectal cancer, etc.
- bc “abl Chronic myeloid leukemia DNAJA1 Placenta HER2 / neu Breast cancer, Ovarian cancer, Gastric cancer
- RPA2 Kidney cancer etc. SSP1 Liver cancer etc. U2AF1L2 Brain tumor
- sensitizing an antigen-presenting cell with a substance refers to reacting the antigen-presenting cell with the substance.
- the substance is directly applied on the surface of the antigen-presenting cell. Or to be presented indirectly.
- co-sensitizing antigen-presenting cells means sensitizing antigen-presenting cells with two or more substances simultaneously, continuously, or intermittently.
- Said substance is preferably bisphosphonate and Z or disease antigen.
- the activation treatment method for antigen-presenting cells of the present invention and the method for producing activated antigen-presenting cells of the present invention will be described in detail based on the following example using rod-shaped cells as antigen-presenting cells.
- the activation treatment of antigen-presenting cells refers to treatment including co-sensitization of antigen-presenting cells with bisphosphonate and a disease antigen as described above.
- the preparation of antigen-presenting cells (in this example, rod-shaped cells) will be described.
- the preparation of rod cells begins with obtaining a sample to obtain rod precursor cells.
- peripheral blood, bone marrow fluid, umbilical cord blood and the like can be used.
- Peripheral blood is preferably used in consideration of availability and low burden on patients. It is preferable to collect blood in such a volume that does not burden the provider.
- a method for collecting blood collection of whole blood using a vacuum blood collection tube, a blood collection node, or the like can be used.
- peripheral blood mononuclear cells it is possible to obtain peripheral blood mononuclear cells directly by using a method of collecting mononuclear cell components using a component blood collection device. You can add heparin and citrate so that the collected blood does not clot.
- mononuclear cells containing progenitor cells of rod-shaped cells are separated from the collected blood.
- any method for separating nucleated cells from erythrocyte power can be used.
- methods utilizing Ficoll fractionation or Ficoll-Paque density gradients or elution are commonly used.
- the collected cells are preferably washed several times with a medium, physiological saline, phosphate buffered saline (hereinafter referred to as PBS) or the like in order to remove platelets and the like.
- PBS physiological saline
- PBS phosphate buffered saline
- monocytes (CD14 positive cells) that are progenitor cells of the rod-shaped cells are separated from the recovered mononuclear cells.
- CD14 is known to be a marker expressed on monocytes, which are progenitor cells of rod cells. Therefore, Magnetic Cell using anti-CD14 antibody magnetic beads
- Monocytes can be isolated and recovered using Sorting (Miltenyi Biotec, hereinafter referred to as MACS). This method is preferable because it is simple and the recovery rate of monocyte cells is high.
- the recovered mononuclear cells are transferred to a culture flask and cultured at 34 ° C to 38 ° C, more preferably 37 ° C, 2% to 10%, more preferably 5% CO for 1 hour or longer.
- AIM-V medium Invitrogen
- RPMI-1640 medium Invitrogen
- Dulbecco's modified Eagle medium Invitrogen, hereinafter referred to as DMEM
- TIL Immuno-Biological Laboratories, Inc.
- KBM epidermal keratinocyte medium
- IMEM epidermal keratinocyte medium
- immature rod cells are obtained by adding differentiation-inducing factors to the culture medium and culturing the precursor cells of the rod cells.
- differentiation-inducing factors Any of the cytodynamics can be used as the differentiation inducing factor.
- GM-CSF granulocyte-macrophage colony-stimulating factor
- IL 4 interleukin 4
- SCF stem self-actor
- IL-13 tumor necrosis factor ⁇
- TNF- ⁇ tumor necrosis factor ⁇
- IL-1 IL-2
- IL-3 IL-3
- IL 4 a combination of GM-CSF and IL 4 can be used for efficient induction. Culture is performed at 34 ° C to 38 ° C, preferably 37 ° C, 2% to 10%, preferably 5% CO
- the culture period is preferably 5-7 days.
- PGE Prostaglandin E
- IL-1 IL-2, IL3, etc.
- Culturing is performed under conditions of 34 ° C to 38 ° C, preferably 37 ° C, 2% to 10%, preferably 5% CO, and the culture time is 24 to 4
- hematopoietic stem cells (CD34 positive cells) were collected as progenitor cells of the rod-shaped cells, and GM-CSF, TNF-a and fit 3 ligand (FL), c-kit ligand (SCF), or thrombopoietin ( TPO) alone or a combination thereof is added to obtain immature rod cells or mature rod cells, or directly using a specific gravity solution such as Percoll from blood or peripheral blood mononuclear cells separated. A method for collecting the rod-shaped cell fraction can also be used.
- the obtained antigen-presenting cells in this example, the immature rod cells or mature rod cells. Cells) with bisphosphonates and disease antigens.
- the concentration of bisphosphonate is not particularly limited as long as it is a concentration that normally sensitizes cells with bisphosphonate.
- the literature [The Journal of Immunology, 200 1, Vol. 166, 5508-5514, or Blood , 2001, Vol. 98, No. 5, 1616—161 8], 0. 001 M force and 20 M force, or even from 0.001 M to 5 ⁇ . Preferably there is.
- the concentration of the disease antigen is not particularly limited as long as it is usually a concentration that sensitizes rod-shaped cells with the disease antigen.
- a disease antigen protein or peptide as described above, the literature [Cancer Research, 1999, Vol. 59, 2167-2173, The Journal of Immunology, 1995, Vol. 154, 2257-2265, or The Journal of Immunology, 1994, 153, 996—1003] [This is described! Speaking] [0.01-20 g / mL is preferred, and 0.1-2 / ⁇ 8 It is preferable that ⁇ .
- cancer cell or cancer cell line when sensitizing a rod-shaped cell with a cell group containing apoptotic cells and sputum or necrotic cells as a disease antigen, for example, 1) cancer cell or cancer cell line 2) Cancer cells or cancer cell lines are formed by UV irradiation (ljZcm 2 'sec for 2 minutes), 3) Cancer cells or cancer cell lines 85 A method of forming by heat treatment at 5 ° C for 10 minutes.
- the activated antigen-presenting cells of the present invention (in this example, activated rod cells) prepared (produced) by the activation treatment method of the present invention are disease antigen-specific CD8 + CTL and Z Alternatively, immunocompetent cells that predominantly contain ⁇ ⁇ ⁇ cells can be efficiently induced.
- the activated antigen-presenting cell of the present invention can induce immunocompetent cells that predominantly contain disease antigen-specific CTL and Z or ⁇ ⁇ cells. It can be used as a medicine. In particular, as a medicine, it is preferably used as a therapeutic / preventive agent for cancer and epilepsy or infectious diseases.
- immunocompetent cells are recognized as antigen specificities including ⁇ cells, iNKT cells, ⁇ cells (Natural Killer Cells), B cells, monocytes, rod cells, macrophages and the like and Z Alternatively, it refers to a cell group capable of engaging in a specific immune reaction or a group of cells containing one or more of them.
- disease antigen-specific CD8 + CTL and Z or ⁇ The predominance of T cells means that the ratio of disease antigen-specific CD8 + CTL and ⁇ or ⁇ ⁇ ⁇ cells and the number of ⁇ or cells are increased as compared with those before stimulation.
- the activated antigen-presenting cell of the present invention when used in vitro, can be used as a composition capable of inducing immunocompetent cells containing predominantly disease antigen-specific CD8 + CTL and Z or ⁇ ⁇ cells. Is possible.
- the active antigen-presenting cells of the present invention are superior to disease antigen-specific CD 8 + CTL and / or ⁇ ⁇ ⁇ cells after washing and removing free bisphosphonate and disease antigens when used in vivo. It can be used as a vaccine such as a rod-shaped cell vaccine that can induce immunocompetent cells contained in the above.
- cyto force-in for example, IL-2
- other proteins for example, albumin
- the activated antigen-presenting cells (activated rod cells) obtained in the first embodiment described above are collected by a centrifugation method or the like.
- the collected cells are washed.
- physiological saline, PBS or the like As long as the liquid to be washed is isotonic and can be used as a medicine, it is possible to use a deviation.
- physiological saline, PBS or the like it is preferable to use physiological saline, PBS or the like.
- the collected rod-shaped cells can be used as a medicament by being suspended in physiological saline.
- serum components such as albumin and cyto force-in can be added as necessary.
- the medicament is preferably used as a therapeutic / preventive agent for cancer and Z or infectious diseases.
- the present invention includes the use of the active antigen presenting cells of the present invention for the manufacture of a medicament for cancer and Z or infection.
- the activated antigen-presenting cell of the present invention obtained in the first embodiment described above (activated rod-shaped cell) ), Or by administering the medicament of the present invention obtained by the second embodiment, it is possible to treat / prevent cancer and Z or infectious diseases.
- the number of cells to be administered can be appropriately selected according to the administration method and the patient's condition, and is not particularly limited. Usually, it is preferably 10 6 to 10 8 per person in a single administration, more preferably 10 7 Z or more.
- the number of doses varies depending on the patient's condition, but usually 4 to 6 doses are taken as one course.
- the administration interval depends on the number of rod cells to be administered and is not particularly limited. It is usually preferred to be once a week to once a month, and if the number of rod cells to be administered is 5 x 10 6 once every 2 weeks and 2 x 10 7 or more Administration once a month is preferred.
- the method of administration is not particularly limited, but it can be injected intravenously, subcutaneously, intradermally, directly into the regional lymph node, directly into the lesion, or administered systemically as an infusion It is also possible. Alternatively, arterial forces near the lesion can be injected.
- These disease antigen-specific CTLs and ⁇ or ⁇ ⁇ ⁇ cells are cytokines such as interferon ⁇ (hereinafter referred to as IFN y) that directly kill cancer cells and infected cells. Since these cells can be indirectly injured through the blood, it can be effectively used for prevention of various treatments such as cancer and infectious diseases.
- IFN y interferon ⁇
- Advantages of using the activated antigen-presenting cell of the present invention as a vaccine include the following. That is, when a rod-shaped cell sensitized with only a conventional disease antigen is used as a vaccine, only the disease antigen-specific CD8 + CTL is activated.
- the vaccine of activated antigen-presenting cells of the present invention can also activate ⁇ cells in addition to the activity of disease antigen-specific CD8 + CTL.
- these disease antigen-specific CD8 + CTLs and cyto force-in induced from ⁇ or ⁇ ⁇ ⁇ cells activate helper ⁇ cells, ⁇ cells, iNKT cells (invariant Natural Killer T Cells) and B cells. You can do it.
- the humoral and cellular immune systems throughout the living body are activated, and as a result, it is possible to improve the treatment and prevention effect.
- the antigen-presenting cells used for the treatment of active ivy are derived from the patient's self or It is preferably derived from another family with the same HLA. This is because when administered to a patient, the function can be exhibited without being excluded by the patient's own immunity.
- the method for inducing immunocompetent cells of the present invention is a method for inducing immunocompetent cells containing predominantly disease antigen-specific CD8 + CTL and ⁇ or ⁇ ⁇ cells, more specifically, bisphosphonate and disease.
- An induction method comprising a step (i) of sensitizing antigen-presenting cells with an antigen and a step (ii) of culturing the antigen-presenting cells and lymphocytes in a mixed manner simultaneously with or after the sensitization.
- immunocompetent cells include T cells, iNKT cells, NK cells, B cells, monocytes, rod cells, macrophages, etc., as described above, and recognize the specificity of antigens and Z or specific. ⁇ Cells that have the ability to participate in immune responses, or cells that contain one or more of these.
- an antigen-presenting cell for example, a rod-shaped cell
- the antigen-presenting cells and the reaction cells are seeded in a culture vessel and mixed and cultured (step (ii)).
- disease antigen-specific stimulation from the antigen-presenting cells treated with the activity can be activated and the disease antigen-specific CD8 + CTL in the reaction cells can be activated.
- ⁇ in the reaction cell is stimulated by an IPP dsopente nyl diphosphate (isopenterylphosphate) -like molecule presented on the antigen-presenting cell surface by inhibition of the antigen-presenting cell metabolic system by sensitization with bisphosphonate.
- ⁇ cells can be activated.
- IFN y produced from ⁇ ⁇ cells can help further activation and proliferation of the disease antigen specific CD8 + CTL.
- the reactive cells here are, for example, human lymphocytes, and preferably mononuclear cells derived from peripheral blood. This reactive cell is preferably autologous or derived from another family with the same HLA.
- the culture vessel is not particularly limited, and culture plates, petri dishes, flasks, nogs, etc. that are usually used in the field can be used.
- the concentration at which each cell group is seeded can be freely set depending on the situation.
- the mixed culture of the rod-shaped cell and the reactive cell includes for example, it can be cultured using AIM-V medium.
- AIM-V medium commercially available media used for cell culture such as RPMI-1640 medium, DMEM, TIL, KBM, and IMEM can be used. Further, 5% to 20% of bovine serum, FBS, serum such as human plasma, cytodynamic force etc. may be added as necessary.
- the culture is performed at 34 ° C to 38 ° C, preferably 37 ° C, for example, under CO conditions of 2% to 10%, preferably 5%.
- the period is not particularly limited, but is preferably 5 to 21 days, and more preferably 7 to 14 days.
- the number of rod cells and reaction cells to be seeded can be set according to the container to be seeded and the application. Further, the mixing ratio of the rod-shaped cells and the reaction cells can be appropriately set according to the situation, and is not particularly limited.
- the ratio of reaction cells to rod cells is preferably 20: 1 to 2: 1.
- the immunocompetent cells of the present invention that predominantly contain ⁇ cells.
- the immunocompetent cells of the present invention obtained in this way can be stimulated directly or repeatedly with the activated antigen-presenting cells of the present invention, so that a higher proportion of the disease antigen-specific CD 8 + CTL and Z or ⁇ It can be used for immune cell therapy as immunocompetent cells including ⁇ sputum cells, and can be expected to have higher therapeutic and preventive effects against cancer and infectious diseases.
- the advantage of preparing the immunocompetent cells of the present invention in vitro is that cancer cells and infectious cells can be directly killed by repeatedly stimulating reactive cells with the activated antigen-presenting cells of the present invention. Large amount of immunocompetent cells can be easily prepared.
- the immunocompetent cells of the present invention which predominately contain the disease antigen-specific CD8 + CTL and Z or ⁇ sputum cells obtained in the fourth embodiment described above, are collected by centrifugation or the like. .
- the collected cells are washed.
- the liquid to be washed is isotonic, and any liquid can be used as long as it can be used as a medicine.
- physiological saline, PBS or the like it is preferable to use physiological saline, PBS or the like in consideration of administration to a patient.
- the immunocompetent cells that predominantly contain the recovered disease antigen-specific CD8 + CTL and ⁇ or ⁇ ⁇ ⁇ cells It becomes possible to use as a medicine by being suspended in physiological saline.
- the medicament is particularly preferably used as a therapeutic / preventive agent for cancer and Z or infectious diseases. Therefore, as a related embodiment, the present invention includes the use of an active antigen-presenting cell of the present invention for the manufacture of a medicament for cancer and Z or infection.
- the number of cells to be administered can be appropriately selected according to the administration method and the patient's condition, and is not particularly limited. Usually, it is preferable that the number of doses per administration is 10 8 to 10 12 Z people, more preferably 10 9 Z people or more. The number of doses varies depending on the patient's condition, but usually 4 to 6 doses are given as one course.
- the administration interval is not particularly limited, but it is preferable to administer it once every two weeks or once a month, for example.
- the method of administration is not particularly limited, but it can be injected by intravenous, subcutaneous, intracutaneous injection, direct injection into regional lymph nodes, direct injection into the affected area, or as a systemic infusion. It can also be administered.
- the immunocompetent cell of the present invention is preferably derived from the patient's own origin or from another family with the same HLA. This is because, when administered to a patient, it can perform its function without being excluded by the patient's own immune system.
- Seventh embodiment an agent for accelerating the activation of cells that are presented by Kyubara when sensitizing in disease
- the activation promoter for antigen-presenting cells when sensitized with the disease antigen of the present invention contains bisphosphonate as an active ingredient.
- the activation promoter may further comprise a pharmaceutically acceptable excipient and / or carrier.
- the activation promoter is used when sensitizing antigen-presenting cells with a disease antigen in vivo and / or ex vivo, that is, sensitization with a disease antigen. It can be added at the same time as sensitizing with a disease antigen before and after sensitizing with Z or disease antigen.
- Another aspect of the present invention is the use of a bisphosphonate for the production of an activity promoter for antigen-presenting cells when sensitized with a disease antigen.
- the present invention provides treatment for cancer and Z or infection using bisphosphonate.
- HLA-A * 0201 Healthy donor strength Peripheral blood was collected in 30 mL. Mononuclear cells were also obtained from the peripheral blood pressure of this healthy person. At this time, the mononuclear cell layer was recovered using a specific gravity solution for blood cell separation. The recovered cell force was washed several times with AIM-V supplemented with 10% FBS to remove platelets and the like, and then CD14-positive cells were isolated as monocyte components by MACS.
- the surface antigens of the rod-shaped cells obtained by the preparation were detected using a flow cytometer (Epics XL-MCL, Beckman Coulter).
- the target antibody was added to a suspension of the cells to be measured in PBS, followed by staining at 4 ° C for 15 minutes in the dark.
- As the antibody PE-labeled anti-CD14 antibody, anti-CD83 antibody, and anti-HLA-DR antibody (Beckman Coulter) were used. Each antibody isotype was used as a negative control. Stained cells are washed with PBS and measured with Epics XL'MCL. It was.
- cells cultured with GM-CSF and IL-4 showed CD14, CD83 negative, and HLA-DR positive, confirming that they were immature rod cell populations.
- Example 1 3 Preparation of rod-shaped cells and reaction cells sensitized with Zometa (trade name) and disease antigen peptide>
- Zometaron (trade name) (amino acid phosphonate), Zoledronic acid, becomes 0.01 ⁇ in a suspension of immature rod cells or mature rod cells derived from peripheral blood prepared as described above.
- the cells were cultured for about 12 hours.
- the cells used were rod-shaped cells cultured without adding Zometa (trade name) and antigenic peptide.
- CD14 negative cell population mainly T cell population
- DMSO foxoxide
- Example 1 4 Analysis of properties of immunocompetent cells induced by rod-shaped cells sensitized with Zometa (trade name) and disease antigen peptide>
- PE-labeled A27L tetramer (MBL) was first added to cells washed with PBS after culturing. After staining for 15 minutes at room temperature in the dark, FITC-labeled anti-CD8 antibody (BD Pharmingen) was added, and stained at 4 ° C for 15 minutes in the dark. The isotype of each antibody was used for control. Epics XL'MCL was used for cell measurement, and Epics32 was used for analysis of measurement results.
- Table 4b and Fig. 1 show the results of a t-test performed by conducting the same experiment with an increasing number of subjects.
- the proportion of CD8 + CTL obtained using rod-shaped cells sensitized with A27L and Zometa is higher than the proportion of CD8 + CTL obtained using rod-shaped cells sensitized with A27L alone. was found to be significantly different.
- Example 2-1 Analysis of the properties of immunocompetent cells induced by co-culturing rod-like cells and reaction cells that are sensitized in the presence of Zometa (trade name) and A27L>
- Peripheral blood-derived immature rod cells or mature rod cells prepared in Example 1 were seeded on a 24-well plate (SUMILON) at 1 ⁇ 10 5 cells each in a total volume of 1 mL.
- Zometa trade name
- an amino bisphosphonate agent to a concentration of 0.01 M
- Z or A27L to a final concentration of 2 / z gZmL.
- the proportion of ⁇ ⁇ ⁇ cells was calculated using FITC-labeled anti-TCR V ⁇ 9 antibody, ⁇ -labeled anti-TCR pan a / jS antibody, and PC5-labeled anti-CD3 antibody (all Beckman Coulter) . These antibodies were added to the cultured cells washed with PBS, and stained at 4 ° C for 15 minutes in the dark. For each negative control, the isotype of each antibody was used. Epics XL'MCL was used for cell measurement, and Epics32 was used for analysis of measurement results.
- y ⁇ ⁇ ⁇ ⁇ can be obtained by co-cultivating lymphocytes and sympathetic cells in the presence of 0.01 ⁇ Zometa (trade name) and A27L. An increase in cell induction was also confirmed.
- the number of cells was calculated by multiplying the total number of cells by the ratio.
- Example 2-2 IFN y production ability of immunocompetent cells induced by co-cultivating coagulated rod-shaped cells and reactive cells in the presence of Zometa (trade name) and A27L Analysis> Subsequently, the IFN y producing ability of the immunocompetent cells induced by the above mixed culture was analyzed as follows.
- the number of cells indicates per well of an assay plate.
- preculture of mixed culture cells only and preculture of rod cells and A27L alone were also performed.
- the culture volume was adjusted to 100 / zL per lwell.
- 300 L of culture was performed for 3 wells. After blocking, the cells that had been pre-cultured under each condition were seeded at 100 L / well, 3 wells on a plate washed with PBS, and cultured at 37 ° C under 5% CO. cultured cells from well
- Piotin-labeled anti-IFN- ⁇ antibody for detection (clone: 7—B6-1, MABTECH ELISpot for Human Interferon - ⁇ kit) is diluted to 1 ⁇ gZmL with PBS containing 0.5% FBS and added to 100 ⁇ LZwell. Caro. The plate was left at room temperature for 2 hours. The plate was washed 5 times with 200 LZwell PBS. Streptavidin conjugated with alkaline phosphatase (MABTECH ELISpot for Human Interferon— ⁇ kit) was diluted 1: 1000 with PBS containing 0.5% FBS, and 100 LZwell was added. The plate was left at room temperature for 1 hour.
- the plate was washed 5 times with 200 LZwell of PBS.
- BCIP / NBTplus substrate solution (Wako) was added at 100 ⁇ L / wel 1 and allowed to stand until a spot was confirmed in the dark. When spots were confirmed with the naked eye, they were thoroughly washed with distilled water. After confirming that the membrane of the plate was dry, the number of spots was measured using an ELISPot reader (AID Autoimmun Diagnostika GmbH), and the data was analyzed with AID software version 3.1 (AID).
- the MART-1-positive melanoma-derived cancer cell line was collected in a 15 mL tube (BD Falcon) and centrifuged at 1500 rpm for 5 minutes. The pelleted cell line was suspended in 10 mL of AIM-V medium, centrifuged at 1500 rpm for 5 minutes, and washed. The washing operation was repeated twice. The cell lines collected in this way were resuspended in AIM-V to 1 X 10 6 cells ZmL. Add 10 ⁇ camptothecin (sigma) to the cell suspension and grow for 24 hours at 37 ° C and 5% CO
- the cultured cells were collected in a 15 mL tube and centrifuged at 1500 rpm for 5 minutes.
- the pelleted cell line is suspended in 10 mL of AIM-V medium, centrifuged at 1500 rpm for 5 minutes, and washed. did. The washing operation was repeated twice. Cells obtained by centrifugation and washing were used as apoptotic cells.
- Zometa (trade name), an aminobisphosphonate agent, was added to the suspension of immature rod cells.
- the mixture was added to a volume of 01 ⁇ , and a cancer cell line containing the same amount of apoptotic cells as the rods or rod cells was added, and mixed and cultured for about 24 hours.
- apoptotic cells and rod cells cultured for about 24 hours and rod cells cultured without adding Zometa (trade name) or apoptotic cells were used.
- the mature rod-shaped cells obtained here were used as stimulating cells.
- the remaining cells (CD14 negative cell population, mainly T cell population) after isolation of CD14 positive cells for the preparation of rod cells as reactive cells, 10% FBS, 10% dimethyl sulfoxide Cells frozen and stored in AIM-V medium supplemented with (DMSO) were thawed, washed and used. Culturing was performed under conditions of about 37 ° C and 5% CO. 20 UZmL IL-2 was added to this mixed culture solution.
- Peripheral blood-derived immature rod cells prepared in Example 1 were seeded in a 48-well plate at 1 ⁇ 10 5 Zwell.
- MART1 antigen peptide A27L (ELAGIGILTV) was added to each well as a disease antigen peptide to a final concentration of 2 ⁇ gZmL.
- Zometa (trade name) (Novartis), an aminobisphosphonate agent, was added as zoledronic acid to a concentration of 0.01 ⁇ and prepared with no addition.
- IX 10 6 lymphocytes from the same donor to Zwell and mix with rod cells at 37 ° C and 5% CO.
- Lymphocytes on days 13 to 17 after the start of mixed culture were collected.
- HLA-A * 0201 positive, MARTl-positive human melanoma cells 3 ⁇ 4 ⁇ COCB were labeled with PKH-26 (Sigma) to obtain target cells.
- the collected lymphocytes were used as effector cells, mixed so that the effector cells: target cells were 5: 1 or 20: 1, and seeded in a 24-well plate. Incubation was performed for 4 hours at 37 ° C and 5% CO.
- Table 9 below shows the percentage of A27L antigen-specific CD8 + CTL induced by active donor cells co-sensitized with A27L and Zometa for 2 donors, tetramer positive cells.
- 1 shows the results of measuring the mean fluorescence intensity (MFI) and the percentage of apoptosis cells (%) at which Mn is detected.
- MFI mean fluorescence intensity
- % percentage of apoptosis cells
- lymphocytes 13 to 17 days after the start of culture are used as effector cells (E), and MART-1 positive and HLA-A * 0201-positive human melanoma cell lines are used as target cells (T) for mixed culture.
- E effector cells
- T target cells
- the effector cell: target cell ratio of 5: 1 or 20: 1 the lymphocytes stimulated with active rods sympathized with A27L and Zometa were It showed higher target cell toxicity than lymphocytes stimulated with rod-shaped cells sensitized with A27L alone.
- BMLF1 EBV antigen peptide B MLFl
- the remaining cells (CD14-negative cell population, mainly T-cell population) after isolation of CD14-positive cells for the preparation of rod-shaped cells as reaction cells, which are 10% FBS, 10% dimethyl Cells that had been suspended and cryopreserved in AI M-V medium supplemented with sulfoxide (DMSO) were thawed, washed and used.
- BMLF1-specific CD8 + CTL disease antigen-specific CD8 + CTL
- PE-labeled BMLF1 tetramer (MBL) was first added to cells that had been cultured and washed with PBS. After staining for 15 minutes at room temperature in the dark, FITC-labeled anti-CD8 antibody (BD Pharmingen) was added and stained at 4 ° C for 15 minutes in the dark. The isotype of each antibody was used for control. Epics XL'MCL was used for cell measurement, and Epics32 was used for analysis of measurement results.
- MDA-MB-231 (class I antigen HLA-A * 0201) was transfected with the human CD80 gene, a costimulatory molecule, by the lipofussion method.
- Example 6-2 Artificial antigen co-sensitized with Zometa (trade name) and disease antigen peptide Analysis of properties of immunocompetent cells induced by presenting cells>
- the artificial antigen-presenting cells prepared as described above were added to the suspension of MDA-MBZCD80.
- Zometa (trade name) (Novartis), a phosphonate, was added as zoledronic acid to a concentration of 0.01 ⁇ M or 1 ⁇ , and at the same time, MART-1 antigen peptide A27L (ELAGIGILTV) was finally used as a disease antigen peptide.
- the mixture was added to a concentration of 2 / z gZmL, and cultured at 37 ° C under 5% CO for about 12 hours.
- Zometa (trade name) (Novartis), a phosphonate, was added as zoledronic acid to a concentration of 0.01 ⁇ M or 1 ⁇ , and at the same time, MART-1 antigen peptide A27L (ELAGIGILTV) was finally used as a disease antigen peptide.
- the mixture was added to a concentration of 2 / z gZmL, and culture
- activated MDA-MB ZCD80 cells co-sensitized with bisphosphonate and disease antigen peptide, MDA-MBZCD80 cells sensitized with either, and MDA-MBZCD80 cells not sensitized with either were used as stimulating cells.
- the remaining cells CD14-negative cell population, mainly T cell population, HLA-A * 0201
- CD14-positive cells were isolated for the preparation of rod cells as described above.
- the cells that had been suspended and stored frozen in AIM-V medium supplemented with 10% FBS and 10% dimethyl sulfoxide (DMSO) were thawed, washed and used.
- the active antigen-presenting cells of the present invention induce disease antigen-specific CD8 + CT L very efficiently compared to the rod-shaped cells sensitized with only conventional peptides.
- it can be used as a composition for inducing disease antigen-specific CD8 + CTL and Z or ⁇ ⁇ cells.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK06797441.0T DK1930414T3 (da) | 2005-09-08 | 2006-09-05 | Fremgangsmåde til aktiveringsbehandling af antigenpræsenterende celle |
AU2006288348A AU2006288348B2 (en) | 2005-09-08 | 2006-09-05 | Method for activation treatment of antigen-presenting cell |
JP2007534425A JP5384827B2 (ja) | 2005-09-08 | 2006-09-05 | 抗原提示細胞の活性化処理方法 |
EP06797441A EP1930414B1 (en) | 2005-09-08 | 2006-09-05 | Method for activation treatment of antigen-presenting cell |
KR1020087007237A KR101419711B1 (ko) | 2005-09-08 | 2006-09-05 | 항원제시세포의 활성화 처리방법 |
CN200680032855.6A CN101258238B (zh) | 2005-09-08 | 2006-09-05 | 抗原呈递细胞的活化处理方法 |
US12/066,313 US8609410B2 (en) | 2005-09-08 | 2006-09-05 | Method for activation treatment of antigen-presenting cell |
ES06797441T ES2391573T3 (es) | 2005-09-08 | 2006-09-05 | Método para el tratamiento de activación de una célula presentadora de antígeno |
US14/077,671 US20140073050A1 (en) | 2005-09-08 | 2013-11-12 | Method for activation treatment of antigen-presenting cell |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-295598 | 2005-09-08 | ||
JP2005295598 | 2005-09-08 | ||
JP2006-112571 | 2006-04-14 | ||
JP2006112571 | 2006-04-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/066,313 A-371-Of-International US8609410B2 (en) | 2005-09-08 | 2006-09-05 | Method for activation treatment of antigen-presenting cell |
US14/077,671 Division US20140073050A1 (en) | 2005-09-08 | 2013-11-12 | Method for activation treatment of antigen-presenting cell |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007029689A1 true WO2007029689A1 (ja) | 2007-03-15 |
Family
ID=37835809
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/317535 WO2007029689A1 (ja) | 2005-09-08 | 2006-09-05 | 抗原提示細胞の活性化処理方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8609410B2 (ja) |
EP (1) | EP1930414B1 (ja) |
JP (2) | JP5384827B2 (ja) |
KR (1) | KR101419711B1 (ja) |
CN (1) | CN101258238B (ja) |
AU (1) | AU2006288348B2 (ja) |
DK (1) | DK1930414T3 (ja) |
ES (1) | ES2391573T3 (ja) |
WO (1) | WO2007029689A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010001599A1 (ja) | 2008-07-01 | 2010-01-07 | 株式会社メディネット | CTLとγδT細胞の同時誘導方法 |
WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
WO2016166544A1 (en) | 2015-04-15 | 2016-10-20 | Tc Biopharm Ltd | Modified gamma delta cells and uses thereof |
US10471141B2 (en) | 2014-09-03 | 2019-11-12 | Nitto Denko Corporation | Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity |
US10925936B2 (en) | 2014-09-03 | 2021-02-23 | Nitto Denko Corporation | Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates |
JP2022105179A (ja) * | 2015-09-09 | 2022-07-12 | 清華大学 | 効果的なワクチンアジュバントとするメバロン酸経路の阻害剤 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
EP1788078B1 (en) * | 2004-07-08 | 2012-02-08 | Medinet., Co. Ltd. | Dentritic cell drug containing the dentritic cell, therapeutic method using the dentritic cell and method of culturing gamma delta t cell |
WO2012054807A2 (en) | 2010-10-22 | 2012-04-26 | President And Fellows Of Harvard College | Vaccines comprising bisphosphonate and methods of use thereof |
WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
CN105073776B (zh) | 2012-11-13 | 2019-04-12 | 拜恩科技股份公司 | 用于治疗表达紧密连接蛋白的癌症疾病的制剂 |
CN102994448A (zh) * | 2012-12-13 | 2013-03-27 | 上海柯莱逊生物技术有限公司 | 一种体外扩增γδT细胞的方法 |
CN104651308A (zh) * | 2013-11-22 | 2015-05-27 | 深圳先进技术研究院 | 一种用磷酸盐扩增γδT细胞的方法及其应用 |
CN106190972A (zh) * | 2015-04-30 | 2016-12-07 | 广州复大医疗股份有限公司 | 一种外周血γδT细胞的诱导扩增培养方法 |
SG11201809402VA (en) * | 2016-04-28 | 2018-11-29 | Riken | Technology for efficient activation of nkt cells |
US20210363590A1 (en) * | 2018-05-21 | 2021-11-25 | Nanostring Technologies, Inc. | Molecular gene signatures and methods of using same |
CN110272870A (zh) * | 2019-05-16 | 2019-09-24 | 安徽瑞达健康产业有限公司 | 一种细胞组合物在癌细胞nci-h1975上的应用 |
CN112089840B (zh) * | 2020-10-27 | 2022-04-12 | 中南大学湘雅三医院 | Ktn1-as1的抑制剂在制备治疗膀胱癌药物中的应用 |
CN113755599B (zh) * | 2021-10-14 | 2023-12-26 | 四川大学华西医院 | Grb7基因在结直肠癌的诊断、预后检测评价和药物制备中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
WO2006006638A1 (ja) | 2004-07-08 | 2006-01-19 | Medinet Co., Ltd | 樹状細胞、該樹状細胞を含む医薬、該樹状細胞を用いた治療方法およびγδT細胞の培養方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
GB0012209D0 (en) * | 2000-05-19 | 2000-07-12 | Novartis Ag | Organic compounds |
US20040014724A1 (en) * | 2001-05-09 | 2004-01-22 | Seaman John J. | Method of administering a bisphosphonate |
EP1427445A4 (en) * | 2001-08-30 | 2006-09-06 | 3M Innovative Properties Co | METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES |
-
2006
- 2006-09-05 ES ES06797441T patent/ES2391573T3/es active Active
- 2006-09-05 KR KR1020087007237A patent/KR101419711B1/ko active IP Right Grant
- 2006-09-05 AU AU2006288348A patent/AU2006288348B2/en active Active
- 2006-09-05 WO PCT/JP2006/317535 patent/WO2007029689A1/ja active Application Filing
- 2006-09-05 CN CN200680032855.6A patent/CN101258238B/zh active Active
- 2006-09-05 JP JP2007534425A patent/JP5384827B2/ja active Active
- 2006-09-05 EP EP06797441A patent/EP1930414B1/en active Active
- 2006-09-05 DK DK06797441.0T patent/DK1930414T3/da active
- 2006-09-05 US US12/066,313 patent/US8609410B2/en active Active
-
2013
- 2013-02-18 JP JP2013029172A patent/JP5307944B2/ja active Active
- 2013-11-12 US US14/077,671 patent/US20140073050A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6821778B1 (en) | 1993-12-01 | 2004-11-23 | The Board Of Trustees Of Leland Stanford Junior University | Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells |
WO2006006638A1 (ja) | 2004-07-08 | 2006-01-19 | Medinet Co., Ltd | 樹状細胞、該樹状細胞を含む医薬、該樹状細胞を用いた治療方法およびγδT細胞の培養方法 |
Non-Patent Citations (13)
Title |
---|
CONTI ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 174, 2005, pages 252 - 260 |
KATO ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 5092 |
KUNZMANN ET AL., BLOOD, vol. 102, no. 11, 2003, pages 39B |
KUNZMANN ET AL., BLOOD, vol. 96, 2000, pages 384 |
KUNZMANN V. ET AL.: "Crucial role of monocytes in aminobisphosphonate recognition by gammadelta T cells", BLOOD, vol. 102, no. 11, 2003, pages 39B (ABSTRACT #3859), XP003000483 * |
KUNZMANN V. ET AL.: "Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma", BLOOD, vol. 96, no. 2, 2000, pages 384 - 392, XP002223785 * |
MIYAGAWA ET AL., THE JOURNAL OF IMMUNOLOGY, vol. 166, 2001, pages 5508 |
MIYAGAWA F. ET AL.: "Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gammadelta T cells by aminobisphosphonate antigen", J. IMMUNOL., vol. 166, 2001, pages 5508 - 5514, XP003000482 * |
SASAWATARI S. ET AL.: "Jojosaiboyo Kogenteijisaibo (artificial Antigen Presenting cells; aAPC) no Kaihatsu", THE JAPANESE SOCIETY FOR IMMUNOLOGY GAKUJUTSU SHUKAI KIROKU, vol. 35, 15 November 2005 (2005-11-15), pages 131 (ABSTRACT 1-I-W17-20-P), XP003009782 * |
See also references of EP1930414A4 |
TANAKA ET AL., BIO CLINICA, vol. 19, no. 5, 2004, pages 439 |
TANAKA Y.: "Hito gammadelta-gata T Saibo no Yakuwari", BIO CLINICA, vol. 19, no. 5, 2004, pages 439 - 444, XP003009781 * |
WILHELM, BLOOD, vol. 102, no. 1, 2003, pages 200 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010001599A1 (ja) | 2008-07-01 | 2010-01-07 | 株式会社メディネット | CTLとγδT細胞の同時誘導方法 |
CN102137925A (zh) * | 2008-07-01 | 2011-07-27 | 迈世耐特股份公司 | 同时诱导CTL和γδT细胞的方法 |
CN102137925B (zh) * | 2008-07-01 | 2014-12-10 | 迈世耐特股份公司 | 同时诱导CTL和γδT细胞的方法 |
US8962313B2 (en) | 2008-07-01 | 2015-02-24 | Medinet Co., Ltd. | Method for the simultaneous induction of CTL and γδT cell |
WO2016005752A1 (en) | 2014-07-09 | 2016-01-14 | Tc Biopharm Ltd | Gamma delta t cells and uses thereof |
US10471141B2 (en) | 2014-09-03 | 2019-11-12 | Nitto Denko Corporation | Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity |
US10925936B2 (en) | 2014-09-03 | 2021-02-23 | Nitto Denko Corporation | Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates |
WO2016166544A1 (en) | 2015-04-15 | 2016-10-20 | Tc Biopharm Ltd | Modified gamma delta cells and uses thereof |
JP2022105179A (ja) * | 2015-09-09 | 2022-07-12 | 清華大学 | 効果的なワクチンアジュバントとするメバロン酸経路の阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
EP1930414B1 (en) | 2012-07-18 |
JP5307944B2 (ja) | 2013-10-02 |
AU2006288348A1 (en) | 2007-03-15 |
US20090104161A1 (en) | 2009-04-23 |
JPWO2007029689A1 (ja) | 2009-03-19 |
JP5384827B2 (ja) | 2014-01-08 |
US20140073050A1 (en) | 2014-03-13 |
EP1930414A4 (en) | 2009-04-15 |
EP1930414A1 (en) | 2008-06-11 |
US8609410B2 (en) | 2013-12-17 |
JP2013150609A (ja) | 2013-08-08 |
CN101258238A (zh) | 2008-09-03 |
CN101258238B (zh) | 2014-07-09 |
ES2391573T3 (es) | 2012-11-27 |
KR20080059166A (ko) | 2008-06-26 |
AU2006288348B2 (en) | 2012-05-03 |
DK1930414T3 (da) | 2012-10-22 |
KR101419711B1 (ko) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5307944B2 (ja) | 抗原提示細胞の活性化処理方法 | |
ES2535835T3 (es) | Composiciones para la preparación de células dendríticas maduras | |
EP2459707B1 (en) | Compositions and methods of preparing alloreactive cytotoxic t cells | |
EP2311470B1 (en) | Method for simultaneous induction of ctl and gamma delta t cell | |
EP1788078B1 (en) | Dentritic cell drug containing the dentritic cell, therapeutic method using the dentritic cell and method of culturing gamma delta t cell | |
CA2796379A1 (en) | Method for proliferation of antigen-specific t cells | |
WO2007040105A1 (ja) | T細胞集団の製造方法 | |
US9694059B2 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
JP2010259373A (ja) | 抗原提示細胞の活性化処理方法 | |
RU2645464C1 (ru) | Способ иммунотерапии рака молочной железы с помощью антиген-активированных дендритных клеток |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680032855.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007534425 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12066313 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006288348 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020087007237 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006797441 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2737/DELNP/2008 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2006287103 Country of ref document: AU Date of ref document: 20060821 Kind code of ref document: A |